Professional summary of a JAMA Network Open research letter
Authors: Yonghong Li, PhD; Carmen H. Tong, MS; Tara S. Givens, PhD; Ross M. Boyce, MD
Clinical Bottom Line
In this national cohort of 193,260 individuals tested for tick-borne disease (2021–2025), seropositivity for Borrelia burgdorferi (Lyme disease) was strongly associated with seropositivity for other tick-borne pathogens. Patients with laboratory evidence of Lyme disease were roughly 4.5 times more likely to also test seropositive for anaplasmosis, babesiosis, or ehrlichiosis than patients without it (29.5% vs 5.5%; adjusted seropositivity ratio, 4.46; 95% CI, 4.30–4.63). The association was strongest in the Northeast. For clinicians, this reinforces the value of screening for co-infection — especially babesiosis, which does not respond to doxycycline — in patients being evaluated for Lyme disease, particularly in endemic regions and during peak tick season.
Background
Ixodes ticks that transmit B burgdorferi can simultaneously carry Anaplasma phagocytophilum and Babesia microti, so a single tick bite can transmit more than one pathogen. Co-infection is known to complicate both diagnosis and treatment, but how often it actually occurs — and how large a clinical burden it represents — has remained poorly characterized and is likely underappreciated in practice. This study set out to quantify how frequently antibodies to other tick-borne pathogens co-occur with B burgdorferi antibodies among patients undergoing serologic testing for tick-borne disease.
Methods
This retrospective cohort study used the Quest Diagnostics national laboratory database to identify 193,260 unique individuals who underwent a first tick-borne disease serology panel (antibodies to B burgdorferi, A phagocytophilum, B microti, and Ehrlichia spp.) between January 2021 and December 2025. Seropositivity ratios comparing B burgdorferi-positive and -negative individuals were estimated with a log-binomial regression model adjusted for age, sex, testing month, and US Census region.
Key Results
Seropositivity for B burgdorferi was found in 5.0% of the cohort, with A phagocytophilum, B microti, and Ehrlichia spp. detected in 3.1%, 3.4%, and 1.0%, respectively.

Individuals seropositive for B burgdorferi were far more likely to also carry antibodies to another tick-borne pathogen than those who were seronegative — 29.5% vs 5.5% (adjusted seropositivity ratio, 4.46; 95% CI, 4.30–4.63; P < .001).

This association held across all four US Census regions but was most pronounced in the Northeast, where 31.1% of B burgdorferi-seropositive individuals were also seropositive for another pathogen, compared with 13.6%–16.6% elsewhere. Antibody-class patterns also tracked together: B burgdorferi IgM correlated with IgM to all three other pathogens, and B burgdorferi IgG correlated with B microti and A phagocytophilum IgG, but not with Ehrlichia IgG.
Clinical Implications
These findings support maintaining a high index of suspicion for non-Lyme tick-borne co-infection in any patient with suspected or confirmed Lyme disease, particularly in the Northeast. Because babesiosis does not respond to doxycycline (the first-line treatment for Lyme disease), clinicians should consider targeted testing — and, where clinically appropriate, adjusted empiric treatment — when Babesia infection is plausible. The authors also flag important caveats: coseropositivity does not prove active co-infection, the clinical indications driving testing and the stage of illness were unknown, and cross-reactivity of the less specific IgM assays may inflate apparent coseropositivity. The results should therefore inform clinical suspicion rather than be read as a true co-infection rate.
Source: Li Y, Tong CH, Givens TS, Boyce RM. Coseropositivity to Tick-Borne Pathogens Among Patients Suspected to Have Lyme Disease. JAMA Network Open. 2026;9(9):e2634800. doi:10.1001/jamanetworkopen.2026.34800
© 2026 Li Y et al. Open access under the CC BY-NC-ND license (no alteration or commercial use, including text/data mining or AI training).
(C) Lyme Borreliosis Alapítvány




